BioMarin

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade BioMarin 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BMRN

BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. 

CEO
Alexander Hardy
CEOAlexander Hardy
Employees
3,040
Employees3,040
Headquarters
San Rafael, California
HeadquartersSan Rafael, California
Founded
1997
Founded1997
Employees
3,040
Employees3,040

BMRN Key Statistics

Market cap
11.85B
Market cap11.85B
Price-Earnings ratio
33.95
Price-Earnings ratio33.95
Dividend yield
Dividend yield
Average volume
2.81M
Average volume2.81M
High today
$63.22
High today$63.22
Low today
$60.59
Low today$60.59
Open price
$60.85
Open price$60.85
Volume
1.68M
Volume1.68M
52 Week high
$73.51
52 Week high$73.51
52 Week low
$50.76
52 Week low$50.76

Stock Snapshot

The current BioMarin(BMRN) stock price is $61.70, with a market capitalization of 11.85B. The stock trades at a price-to-earnings (P/E) ratio of 33.95.

As of 2026-02-27, BioMarin(BMRN) stock has fluctuated between $60.59 and $63.22. The current price stands at $61.70, placing the stock +1.8% above today's low and -2.4% off the high.

The BioMarin(BMRN)'s current trading volume is 1.68M, compared to an average daily volume of 2.81M.

In the last year, BioMarin(BMRN) shares hit a 52-week high of $73.51 and a 52-week low of $50.76.

In the last year, BioMarin(BMRN) shares hit a 52-week high of $73.51 and a 52-week low of $50.76.

BMRN News

TipRanks 1d
BioMarin price target raised to $104 from $98 at Canaccord

Canaccord analyst Whitney Ijem raised the firm’s price target on BioMarin (BMRN) to $104 from $98 and keeps a Buy rating on the shares. The firm said its 4Q25 e...

Simply Wall St 2d
BioMarin Deal Reshapes Amicus Therapeutics Outlook For Growth And Portfolio

BioMarin Pharmaceutical has entered into a definitive agreement to acquire Amicus Therapeutics. The deal marks a major change for Amicus Therapeutics and its c...

BioMarin Deal Reshapes Amicus Therapeutics Outlook For Growth And Portfolio
TipRanks 2d
BioMarin price target lowered to $55 from $60 at H.C. Wainwright

H.C. Wainwright analyst Mitchell Kapoor lowered the firm’s price target on BioMarin (BMRN) to $55 from $60 and keeps a Neutral rating on the shares. The firm sa...

Analyst ratings

77%

of 26 ratings
Buy
76.9%
Hold
23.1%
Sell
0%

More BMRN News

TipRanks 3d
BioMarin Earnings Call Highlights Growth, Pipeline, Deals

Biomarin Pharmaceutical Inc. ((BMRN)) has held its Q4 earnings call. Read on for the main highlights of the call. Claim 50% Off TipRanks Premium Unlock hedge fu...

TipRanks 3d
BioMarin price target lowered to $97 from $102 at BofA

BofA lowered the firm’s price target on BioMarin (BMRN) to $97 from $102 and keeps a Buy rating on the shares. The firm’s lowered target reflects competitive he...

TipRanks 3d
Balanced Risk-Reward Amid Evolving Growth Profile and Rising Competition at BioMarin

William Blair analyst Sami Corwin has maintained their neutral stance on BMRN stock, giving a Hold rating on February 17. Sami Corwin has given his Hold rating...

People also own

Based on the portfolios of people who own BMRN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.